Studies of Elevated Parathyroid Activity
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm
About this trial
This is an interventional diagnostic trial for Hyperparathyroidism focused on measuring Hypoglycemia, Genetics, Hyperparathyroidism
Eligibility Criteria
INCLUSION CRITERIA: Patients who have genetically confirmed MEN1 or clinical criteria of MEN1. For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy EXCLUSION CRITERIA: Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure or congestive cardiac failure Patients unable or unwilling to give informed consent Pregnant or lactating women: Pregnant women are excluded from this study because the effects of 68Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 68Ga-DOTATATE in the mother, women who are breastfeeding are also excluded from this study Patients that have recognized concurrent active infection Patients with known hypersensitivity to carbidopa, or who are concurrently taking a nonselective monoamine oxidase (MAO) inhibitor..
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Primary hyperparathyroidism
DOTATATE and F-DOPA
Patients with confirmed or suspected primary hyperparathyroidism or complications
Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA